WO2009157398A1 - 炎症性腸疾患治療剤 - Google Patents
炎症性腸疾患治療剤 Download PDFInfo
- Publication number
- WO2009157398A1 WO2009157398A1 PCT/JP2009/061287 JP2009061287W WO2009157398A1 WO 2009157398 A1 WO2009157398 A1 WO 2009157398A1 JP 2009061287 W JP2009061287 W JP 2009061287W WO 2009157398 A1 WO2009157398 A1 WO 2009157398A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- inflammatory bowel
- bowel disease
- formula
- group
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to an inflammatory intestine containing a heterocyclic derivative represented by the following general formula (1) (hereinafter referred to as “the present heterocyclic derivative (1)”) or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention relates to a disease therapeutic agent.
- R 1 and R 2 are the same or different and are each a halogen atom, alkyl, haloalkyl, arylalkyl, alkoxy, alkylthio, alkoxyalkyl, alkylsulfonyl, hydroxy, amino, monoalkylamino, dialkylamino, carboxy
- R 3 and R 4 are the same or different and each represents a hydrogen atom or alkyl
- R 5 represents a hydrogen atom, an alkyl or a halogen atom
- Y represents N or N ⁇ O
- A represents NR 6 and R 6 represents a hydrogen atom, alkyl, alkenyl or cycloalkyl
- D represents alkylene or alkenylene optionally substituted with hydroxy, or A and D together represent a divalent group represented by the following formula (2); [In the formula (2), r represents
- E represents phenylene or a single bond, or D and E together represent a divalent group represented by the following formula (3); [In the formula (3), u represents an integer of 0 to 2, and v represents 0 or 1. ] G represents O, S, SO or SO 2 ; Q represents carboxy, alkoxycarbonyl, tetrazolyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl or a group represented by the following formula (4).
- R 7 is amino, monoalkylamino, dialkylamino, or hydroxy, or halogen atom, alkyl, haloalkyl, arylalkyl, alkoxy, alkylthio, alkoxyalkyl, alkylsulfonyl, hydroxy, amino, monoalkyl Any one of the following 1) to 4) which may be substituted with 1 to 3 substituents selected from the group consisting of amino, dialkylamino, carboxy, cyano and nitro; 1) alkyl, 2) aryl, 3) Aryloxy, 4) A heterocyclic group. ]
- Inflammatory bowel disease is a general term for diseases of unknown cause that cause chronic inflammation and / or ulcers in the mucosa of the large and small intestines, represented by ulcerative colitis and Crohn's disease.
- IBD Inflammatory Bowel Disease
- the problem is that social life is impaired due to dietary restrictions and the number of defecations.
- the autoimmune abnormality theory and the intestinal bacteria theory have been reported as the cause of the inflammatory bowel disease, it has not yet been clarified and no cure for the cure has been found.
- this heterocyclic derivative (1) or a pharmaceutically acceptable salt thereof has already been reported to be useful as a PGI 2 receptor agonist in the treatment of pulmonary hypertension and obstructive arteriosclerosis (for example, see Patent Document 1).
- An object of the present invention is mainly to provide a novel therapeutic agent for inflammatory bowel disease.
- the present inventor has found that the present heterocyclic derivative (1) has a therapeutic effect on colitis caused by administering a dextran sulfate aqueous solution in rats, and has completed the present invention.
- Examples of the present invention include a therapeutic agent for inflammatory bowel disease containing the present heterocyclic derivative (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
- FIG. 1 shows the effect of suppressing the reduction of the large intestine.
- the vertical axis represents the length (mm) of the large intestine.
- FIG. 2 shows the variation in score for colitis symptoms.
- the vertical axis represents the symptom score
- the horizontal axis represents the number of days (days) from the start of free drinking of the dextran sulfate aqueous solution.
- a triangle mark indicates a control group
- a square mark indicates 2- ⁇ 4- [N- (5,6-diphenylpyrazin-2-yl) -N-isopropylamino] butyloxy ⁇ -N- (methylsulfonyl) acetamide (
- each group to which “Compound A” is administered is represented.
- R 1 and R 2 are the same or different and are phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, alkyl and alkoxy;
- R 3 and R 4 are the same or different and each represents a hydrogen atom or alkyl;
- R 5 is a hydrogen atom, Y is N,
- A is NR 6 ,
- R 6 is alkyl,
- D is alkylene
- E is a single bond,
- G O,
- Q is carboxy or a group represented by formula (4),
- R 7 is amino, monoalkylamino, dialkylamino, or hydroxy, or a halogen atom, alkyl, haloalkyl, arylalkyl, alkoxy, alkylthio, alkoxyalkyl Any one of the following 1) to 4) optionally substituted with 1 to 3 substituents selected from the group consisting of alkylsulfonyl, hydroxy, amino
- Compound A 2- ⁇ 4- [N- (5,6-diphenylpyrazin-2-yl) -N-isopropylamino] butyloxy ⁇ acetic acid (hereinafter referred to as “Compound B”).
- Compound B 2- ⁇ 4- [N- (5,6-diphenylpyrazin-2-yl) -N-isopropylamino] butyloxy ⁇ acetic acid
- alkyl in the present invention is a linear or branched one having 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert- Examples include butyl, n-pentyl, isopentyl, n-hexyl and isohexyl. In particular, those having 1 to 4 carbon atoms are preferred.
- Haloalkyl “Haloalkyl”, “arylalkyl”, “alkylthio”, “alkoxyalkyl”, “alkylsulfonyl”, “monoalkylamino”, “dialkylamino”, “monoalkylcarbazoyl” and “dialkylcarbamoyl” in the present invention
- Examples of the moiety include the same alkyl groups as those described above.
- alkoxy is a straight or branched chain having 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert- Examples include butoxy, n-pentyloxy, isopentyloxy, n-hexyloxy and isohexyloxy. In particular, those having 1 to 4 carbon atoms are preferred.
- alkoxy moiety of “alkoxycarbonyl” and “alkoxyalkyl” in the present invention include the same as the above alkoxy.
- alkenyl is linear or branched having 2 to 6 carbon atoms, such as vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, Examples thereof include 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl and 5-hexenyl. In particular, those having 3 or 4 carbon atoms are preferred.
- cycloalkyl in the present invention include those having 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. In particular, those having 5 to 7 carbon atoms are preferred.
- halogen atom examples include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- aryl includes 6 to 10 carbon atoms, such as phenyl, 1-naphthyl and 2-naphthyl. In particular, phenyl is preferred.
- arylalkyl As the aryl moiety of “arylalkyl” and “aryloxy” in the present invention, the same aryl as the above aryl can be exemplified.
- alkylene in the present invention, linear or branched ones having 1 to 8 carbon atoms such as methylene, ethylene, 1-methylethylene, 2-methylethylene, trimethylene, tetramethylene, pentamethylene, Examples include hexamethylene, heptamethylene, and octamethylene. In particular, those having 3 to 6 carbon atoms are preferred, and those having 4 carbon atoms are particularly preferred.
- alkenylene in the present invention, linear or branched ones having 2 to 8 carbon atoms such as ethenylene, 1-propenylene, 2-propenylene, 1-butenylene, 2-butenylene, 3-butenylene, 1-pentenylene, 2-pentenylene, 3-pentenylene, 4-pentenylene, 4-methyl-3-pentenylene, 1-hexenylene, 2-hexenylene, 3-hexenylene, 4-hexenylene, 5-hexenylene, 1-heptenylene, 2- Examples include heptenylene, 3-heptenylene, 4-heptenylene, 5-heptenylene, 6-heptenylene, 1-octenylene, 2-octenylene, 3-octenylene, 4-octenylene, 5-octenylene, 6-octenylene and 7-octenylene. .
- those having 3 to 6 carbon atoms are preferred, and those having 4 carbon atoms are preferred, and those
- heterocyclic group examples include the following (1) or (2).
- an atom or a sulfur atom such a nitrogen atom or sulfur atom may form an oxide.
- piperidino, piperazinyl, 3-methylpiperazin-1-yl, homopiperazinyl, monophorino, thiomonophorino, 1-pyrrolidinyl, 2-pyrrolidinyl, 2-tetrahydrofuranyl can be mentioned.
- the present heterocyclic derivative (1) can be synthesized by the method described in Patent Document 1 (International Publication No. 02/088084 pamphlet).
- the present heterocyclic derivative (1) can be used as a medicine as a free base or acid, but can also be used in the form of a medically acceptable salt by a known method.
- a salt of inorganic acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, or hydrobromic acid, or acetic acid, List organic acid salts of tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, or camphorsulfonic acid Can do.
- alkali metal salts such as sodium salt and potassium salt
- alkaline earth metal salts such as calcium
- the present heterocyclic derivative (1) has geometric isomers (Z-form and E-form), and each geometric isomer and a mixture thereof are also included in the present heterocyclic derivative (1).
- some of the heterocyclic derivatives (1) have asymmetric carbons, but each optical isomer and their racemates are also included in the heterocyclic derivatives (1).
- the optical isomer is obtained from the racemate obtained as described above using its basicity and using an optically active acid (for example, tartaric acid, dibenzoyltartaric acid, mandelic acid, 10-camphorsulfonic acid), It can be optically resolved by a known method, or can be produced using a previously prepared optically active compound as a raw material.
- Examples of the inflammatory bowel disease according to the present invention include ulcerative colitis, Crohn's disease, intestinal tuberculosis, ischemic colitis, and intestinal ulcer associated with Behcet's disease.
- the therapeutic agent for inflammatory bowel disease comprises the present heterocyclic derivative (1) in a range of 0.01 to 99.5% as it is or in a pharmaceutically acceptable non-toxic and inert carrier. Preferably, it is contained within the range of 0.5 to 90%.
- the carrier examples include solid, semi-solid or liquid diluents, fillers, and other formulation aids. One or more of these can be used.
- the therapeutic agent for inflammatory bowel disease is a solid or liquid dosage unit, powder, capsule, tablet, dragee, granule, powder, suspension, liquid, syrup, elixir, troche
- Any form of oral administration preparations such as oral administration preparations and parenteral administration preparations such as injections and suppositories can be used. It may be a sustained-release preparation.
- oral preparations such as tablets are particularly preferable.
- the powder can be produced by making the present heterocyclic derivative (1) fine.
- the powder can be produced by making the present heterocyclic derivative (1) fine and then mixing it with a finely divided pharmaceutical carrier such as edible carbohydrates such as starch and mannitol.
- a finely divided pharmaceutical carrier such as edible carbohydrates such as starch and mannitol.
- flavor, etc. can be added arbitrarily.
- Capsules are manufactured by first filling the powdered powdered powder or powder as described above into granules as described in the section of tablets, for example, into capsule shells such as gelatin capsules. can do.
- Lubricants and fluidizers such as colloidal silica, talc, magnesium stearate, calcium stearate, solid polyethylene glycol are mixed with powdered powder and powder, and then filled. It can also be manufactured.
- disintegrators and solubilizers are added, such as carboxymethylcellulose, carboxymethylcellulose calcium, low-substituted hydroxypropylcellulose, croscarmellose sodium, carboxymethyl starch sodium, calcium carbonate, sodium carbonate
- the fine powder of the present heterocyclic derivative (1) can be suspended and dispersed in vegetable oil, polyethylene glycol, glycerin, or a surfactant and wrapped in a gelatin sheet to form a soft capsule.
- Tablets are manufactured by adding excipients to the powdered heterocyclic derivative (1) to form a powder mixture, granulating or slugging, then adding a disintegrant or lubricant, and then tableting. can do.
- the powder mixture can be produced by mixing the present heterocyclic derivative (1), which has been appropriately pulverized, with a diluent or a base.
- a binder for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, gelatin, polyvinylpyrrolidone, polyvinyl alcohol
- a dissolution retardant for example, paraffin
- a resorbent for example, a quaternary salt
- An adsorbent for example, bentonite, kaolin or the like
- the powder mixture can first be moistened with a binder such as syrup, starch paste, gum arabic, cellulose solution or polymer solution, stirred and mixed, dried and pulverized into granules.
- a tablet can also be manufactured by directly compressing after mixing this heterocyclic derivative (1) with a fluid inert carrier, without going through the granulation and slagging steps as described above. it can. Film tablets and sugar coatings can be applied to the tablets thus produced.
- a transparent or translucent protective coating made of a shellac hermetic coating, a coating of sugar or polymer material and a polishing coating made of wax can also be used.
- oral dosage forms such as solutions, syrups, troches, and elixirs may also be in dosage unit form so that a given amount contains a certain amount of the heterocyclic derivative (1).
- the syrup can be produced by dissolving the present heterocyclic derivative (1) in a suitable flavor aqueous solution.
- An elixir can be produced by using a non-toxic alcoholic carrier.
- the suspending agent can be produced by dispersing the present heterocyclic derivative (1) in a non-toxic carrier. If necessary, solubilizers and emulsifiers (for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol esters), preservatives, flavoring agents (for example, peppermint oil, saccharin), etc. may be added. it can.
- solubilizers and emulsifiers for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol esters
- preservatives for example, peppermint oil, saccharin, etc.
- a dosage unit formulation for oral administration can be microencapsulated.
- the formulation can also be extended in action time or sustained release by being coated or embedded in a polymer, wax or the like.
- the parenteral preparation can take the form of a liquid dose unit for subcutaneous, intramuscular or intravenous injection, for example, a solution or suspension.
- the parenteral preparation is prepared by suspending or dissolving a certain amount of the heterocyclic derivative (1) in a non-toxic liquid carrier suitable for injection purposes, for example, an aqueous or oily medium, and then suspending the suspension. Or it can manufacture by sterilizing a solution.
- Non-toxic salts and salt solutions can be added to make the injection solution isotonic.
- stabilizers, preservatives, emulsifiers, and the like can be added.
- the suppository is obtained by dissolving the heterocyclic derivative (1) in a low-melting water-soluble or insoluble solid such as polyethylene glycol, cacao butter, semi-synthetic oil [for example, Witepsol (registered trademark)], higher esters ( For example, it can be prepared by dissolving or suspending in myristyl palmitate ester) or a mixture thereof.
- a low-melting water-soluble or insoluble solid such as polyethylene glycol, cacao butter, semi-synthetic oil [for example, Witepsol (registered trademark)], higher esters ( For example, it can be prepared by dissolving or suspending in myristyl palmitate ester) or a mixture thereof.
- the dose of the therapeutic agent for inflammatory bowel disease according to the present invention varies depending on the patient's condition such as body weight and age, administration route, symptom level, etc., but generally this heterocyclic derivative (1 ) Is suitably in the range of 0.001 mg to 100 mg per day, more preferably in the range of 0.01 mg to 10 mg. In some cases, a lower dose may be sufficient, and vice versa. Moreover, it can be administered once to several times a day or at intervals of 1 day to several days.
- Test example 1 (1) Test method F334 type rats (male, 8 weeks old) (manufactured by Japan SLC Co., Ltd.) were allowed to drink 3% dextran sulfate aqueous solution freely for 5 days, and then were allowed to drink tap water freely for 1 day. The test substance was orally administered twice a day simultaneously with the start of drinking 3% dextran sulfate aqueous solution. Six days after the start of administration, the large intestine was removed and its length was measured. As for symptom scores, (1) stool characteristics, (2) occult blood in stool, (3) degree of weight loss from the previous day, as shown in Table 1 below, it was evaluated in five stages, and the average value was calculated did.
- Compound A (5 mg / kg) was used as a test substance.
- the test substance was administered suspended in a 0.5% methylcellulose aqueous solution.
- a 0.5% methylcellulose aqueous solution was administered to the control group.
- Ten rats were used per group.
- a significant difference was tested by t-test with respect to the control group (*: p ⁇ 0.05).
- a significant difference was tested by the t-test with respect to the control group (##: p ⁇ 0.01).
- (2) Results As shown in FIG. 1, the administration of Compound A significantly suppressed the reduction of the large intestine. As shown in FIG. 2, the deterioration of colitis symptoms was significantly suppressed by administering Compound A.
- Test example 2 According to the method described in the literature (Gastroenterology 1992; 102: 1524-1534), trinitrobenzenesulfonic acid or acetic acid is administered to rats to cause colitis.
- Compound A or Compound B is administered before or after administration of trinitrobenzenesulfonic acid or acetic acid, and changes in mucosal permeability, histological changes in the large intestine, changes in the weight of the large intestine, etc. are examined. The pharmacological effect of Compound B is evaluated.
- Test example 3 According to the method described in the literature (Dig Dis Sci 2007; 52: 2095-2103), dextran sulfate sodium is administered to rats to cause colitis.
- the compound A or compound B is administered before or after the administration of dextran sulfate sodium, and the pharmacological effects of compound A and compound B are examined by examining changes in mucosal PGE 2 content, myeloperoxidase activity, etc. evaluate.
- Test example 4 In accordance with the method described in the literature (Int Immunopharmacol 2005; 5: 993-1006), spleen cells derived from IL-10-deficient mice are transplanted into SCID mice to cause colitis. Thereafter, Compound A or Compound B is administered, and the pharmacological effects of Compound A and Compound B are evaluated by examining changes in body weight, changes in fecal properties, and the like.
- Test Example 5 In accordance with the method described in the literature (Pharmacology and Treatment 2008; 36: 293-301), trinitrobenzenesulfonic acid or acetic acid is administered to rats to cause colitis. Pharmacological effects of Compound A and Compound B by administering Compound A or Compound B before or after administration of trinitrobenzenesulfonic acid or acetic acid and examining changes in active oxygen, leukotriene B4 production, etc. To evaluate.
Abstract
Description
R3、R4は、同一又は異なって、水素原子又はアルキルを表し;
R5は水素原子、アルキル又はハロゲン原子を表し;
YはN又はN→Oを表し;
AはNR6を表し、R6は水素原子、アルキル、アルケニル又はシクロアルキルを表し;
Dはヒドロキシで置換されていてもよいアルキレン又はアルケニレンを表すか、又はAとDとが一緒になって、次の式(2)で表される二価の基を表し;
Eは、フェニレン又は単結合を表すか、又はDとEとが一緒になって、次の式(3)で表される二価の基を表し;
Gは、O、S、SO又はSO2を表し;
Qは、カルボキシ、アルコキシカルボニル、テトラゾリル、カルバモイル、モノアルキルカルバモイル、ジアルキルカルバモイル又は次の式(4)で表される基を表す。
1)アルキル、
2)アリール、
3)アリールオキシ、
4)複素環基。]
R1、R2が、同一又は異なって、ハロゲン原子、アルキル及びアルコキシからなる群から選ばれる1~3個の置換基で置換されていてもよいフェニルであり、
R3、R4が、同一又は異なって、水素原子又はアルキルであり、
R5が水素原子であり、
YがNであり、
AがNR6であり、R6がアルキルであり、
Dがアルキレンであり、
Eが単結合であり、
GがOであり、
Qが、カルボキシ又は式(4)で表される基であり、R7が、アミノ、モノアルキルアミノ、ジアルキルアミノ、若しくはヒドロキシ、又はハロゲン原子、アルキル、ハロアルキル、アリールアルキル、アルコキシ、アルキルチオ、アルコキシアルキル、アルキルスルホニル、ヒドロキシ、アミノ、モノアルキルアミノ、ジアルキルアミノ、カルボキシ、シアノ及びニトロからなる群から選ばれる1~3個の置換基で置換されていてもよい下記1)~4)のいずれかの基である化合物が好ましい。
1)アルキル、
2)アリール、
3)アリールオキシ、
4)複素環基
(1)窒素原子、酸素原子及び硫黄原子から選択される1~4個までのヘテロ原子を有する5又は6員の芳香環基、又はそれらのベンゼン縮合環であって、かかる環構成原子が窒素原子又は硫黄原子の場合、かかる窒素原子、硫黄原子はオキシドを形成していてもよい。例えば、1-ピロリル、2-ピロリル、3-ピロリル、3-インドリル、2-フラニル、3-フラニル、3-ベンゾフラニル、2-チエニル、3-チエニル、3-ベンゾチエニル、1,3-オキサゾール-2-イル、4-イソオキサゾリル、2-チアゾリル、5-チアゾリル、2-ベンゾチアゾリル、1-イミダゾリル、2-イミダゾリル、4-イミダゾリル、2-ベンズイミダゾリル、1H-1,2,4-トリアゾール-1-イル、1H-テトラゾール-5-イル、2H-テトラゾール-5-イル、2-ピリジル、3-ピリジル、4-ピリジル、3-ピラゾリル、2-ピリミジニル、4-ピリミジニル、2-ピラジニル、1,3,5-トリアジン-2-イルを挙げることができる。
(2)環構成原子として、窒素原子、酸素原子又は硫黄原子を、同一又は異なって、1~4個含んでいてもよい、4~8員環の飽和環基、又はそれらのベンゼン縮合環基であって、環構成原子が窒素原子又は硫黄原子の場合、かかる窒素原子、硫黄原子はオキシドを形成していてもよい。例えば、ピペリジノ、ピペラジニル、3-メチルピペラジン-1-イル、ホモピペラジニル、モノホリノ、チオモノホリノ、1-ピロリジニル、2-ピロリジニル、2-テトラヒドロフラニルを挙げることができる。
本複素環誘導体(1)が塩基性を示す場合の「塩」としては、例えば、塩酸、硫酸、硝酸、リン酸、フッ化水素酸、若しくは臭化水素酸の無機酸の塩、又は酢酸、酒石酸、乳酸、クエン酸、フマール酸、マレイン酸、コハク酸、メタンスルホン酸、エタンスルホン酸、ベンゼンスルホン酸、p-トルエンスルホン酸、ナフタレンスルホン酸、若しくはカンファースルホン酸の有機酸の塩を挙げることができる。
本複素環誘導体(1)が酸性を示す場合の「塩」としては、例えば、ナトリウム塩、カリウム塩等のアルカリ金属塩、又はカルシウム塩等のアルカリ土類金属塩を挙げることができる。
粉末混合物は、適当に粉末化された本複素環誘導体(1)を希釈剤や基剤と混合することにより製造することができる。必要に応じて、結合剤(例えば、カルボキシメチルセルロースナトリウム、メチルセルロース、ヒドロキシプロピルメチルセルロース、ゼラチン、ポリビニルピロリドン、ポリビニルアルコール)、溶解遅延化剤(例えば、パラフィン)、再吸収剤(例えば、四級塩)、吸着剤(例えばベントナイト、カオリン)等を添加することができる。
粉末混合物は、まず結合剤、例えば、シロップ、澱粉糊、アラビアゴム、セルロース溶液又は高分子物質溶液で湿らせ、攪拌混合し、これを乾燥、粉砕して顆粒とすることができる。このように粉末を顆粒化する代わりに、まず打錠機にかけた後、得られる不完全な形態のスラグを破砕して顆粒にすることも可能である。このようにして作られる顆粒に、滑沢剤としてステアリン酸、ステアリン酸塩、タルク、ミネラルオイル等を添加することにより、互いに付着することを防ぐことができる。
また、錠剤は、上述のように顆粒化やスラグ化の工程を経ることなく、本複素環誘導体(1)を流動性の不活性担体と混合した後に直接打錠することによっても製造することができる。
こうして製造された錠剤にフィルムコーティングや糖衣を施すことができる。シェラックの密閉被膜からなる透明又は半透明の保護被覆、糖や高分子材料の被覆及びワックスよりなる磨上被覆をも用いることができる。
(1)試験方法
F334系ラット(雄性、8週齢)(日本エスエルシー社製)に3%デキストラン硫酸水溶液を5日間自由飲水させ、その後、1日間水道水を自由飲水させた。試験物質は3%デキストラン硫酸水溶液の飲水開始と同時に1日2回経口投与した。投与開始から6日後に大腸を摘出し、その長さを測定した。症状スコアについては、(1)便の性状、(2)便中の潜血、(3)前日からの体重減少の程度について、下記表1に示すように5段階で評価し、その平均値を算出した。試験物質としては、化合物A(5mg/kg)を用いた。試験物質は0.5%メチルセルロース水溶液に懸濁して投与した。対照群には0.5%メチルセルロース水溶液を投与した。1群当たり、10匹のラットを用いた。
(2)結果
図1に示すように、化合物Aを投与することにより、大腸の縮小が有意に抑制された。
図2に示すように、化合物Aを投与することにより、大腸炎の症状の悪化が有意に抑制された。
文献(Gastroenterology 1992;102:1524-1534)に記載の方法に準じて、トリニトロベンゼンスルホン酸又は酢酸をラットに投与し、大腸炎を起こさせる。トリニトロベンゼンスルホン酸又は酢酸の投与前若しくは投与後から、化合物A又は化合物Bを投与し、粘膜の透過性の変化、大腸の組織学的な変化、大腸重量の変化などを調べることにより、化合物A、化合物Bの薬理学的な効果を評価する。
文献(Dig Dis Sci 2007;52:2095-2103)に記載の方法に準じて、デキストラン硫酸ナトリウムをラットに投与し、大腸炎を起こさせる。デキストラン硫酸ナトリウムの投与前若しくは投与後から、化合物A又は化合物Bを投与し、粘膜PGE2含量の変化、ミエロペルオキシダーゼ活性の変化などを調べることにより、化合物A、化合物Bの薬理学的な効果を評価する。
文献(Int Immunopharmacol 2005;5:993-1006)に記載の方法に準じて、IL-10欠損マウス由来の脾臓細胞をSCIDマウスに移植し、大腸炎を起こさせる。その後、化合物A又は化合物Bを投与し、体重の変化、便性状の変化などを調べることにより、化合物A、化合物Bの薬理学的な効果を評価する。
文献(薬理と治療 2008;36:293-301)に記載の方法に準じて、トリニトロベンゼンスルホン酸又は酢酸をラットに投与し、大腸炎を起こさせる。トリニトロベンゼンスルホン酸又は酢酸の投与前若しくは投与後から、化合物A又は化合物Bを投与し、活性酸素の変化やロイコトリエンB4産生の変化などを調べることにより、化合物A、化合物Bの薬理学的な効果を評価する。
Claims (5)
- 次の一般式(1)で表される複素環誘導体又はその医薬上許容される塩を有効成分として含有する炎症性腸疾患治療剤;
R3、R4は、同一又は異なって、水素原子又はアルキルを表し;
R5は水素原子、アルキル又はハロゲン原子を表し;
YはN又はN→Oを表し;
AはNR6を表し、R6は水素原子、アルキル、アルケニル又はシクロアルキルを表し;
Dはヒドロキシで置換されていてもよいアルキレン又はアルケニレンを表すか、又はAとDとが一緒になって、次の式(2)で表される二価の基を表し;
Eは、フェニレン又は単結合を表すか、又はDとEとが一緒になって、次の式(3)で表される二価の基を表し;
Gは、O、S、SO又はSO2を表し;
Qは、カルボキシ、アルコキシカルボニル、テトラゾリル、カルバモイル、モノアルキルカルバモイル、ジアルキルカルバモイル又は次の式(4)で表される基を表す。
1)アルキル、
2)アリール、
3)アリールオキシ、
4)複素環基。] - 複素環誘導体(1)において、R1、R2が、同一又は異なって、ハロゲン原子、アルキル及びアルコキシからなる群から選ばれる1~3個の置換基で置換されていてもよいフェニルであり、
R3、R4が、同一又は異なって、水素原子又はアルキルであり、
R5が水素原子であり、
YがNであり、
AがNR6であり、R6がアルキルであり、
Dがアルキレンであり、
Eが単結合であり、
GがOであり、
Qが、カルボキシ又は式(4)で表される基であり、R7が、アミノ、モノアルキルアミノ、ジアルキルアミノ、若しくはヒドロキシ、又はハロゲン原子、アルキル、ハロアルキル、アリールアルキル、アルコキシ、アルキルチオ、アルコキシアルキル、アルキルスルホニル、ヒドロキシ、アミノ、モノアルキルアミノ、ジアルキルアミノ、カルボキシ、シアノ及びニトロからなる群から選ばれる1~3個の置換基で置換されていてもよい下記1)~4)のいずれかの基である、請求項1に記載の炎症性腸疾患治療剤。
1)アルキル、
2)アリール、
3)アリールオキシ、
4)複素環基 - 炎症性腸疾患が、潰瘍性大腸炎、クローン病、腸結核、虚血性大腸炎又はベーチェット病に伴う腸潰瘍である、請求項1に記載の炎症性腸疾患治療剤。
- 2-{4-[N-(5,6-ジフェニルピラジン-2-イル)-N-イソプロピルアミノ]ブチルオキシ}酢酸若しくは2-{4-[N-(5,6-ジフェニルピラジン-2-イル)-N-イソプロピルアミノ]ブチルオキシ}-N-(メチルスルホニル)アセトアミド、又はその医薬上許容される塩を有効成分として含有する炎症性腸疾患治療剤。
- 炎症性腸疾患が、潰瘍性大腸炎、クローン病、腸結核、虚血性大腸炎又はベーチェット病に伴う腸潰瘍である、請求項4に記載の炎症性腸疾患治療剤。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010517993A JP5527206B2 (ja) | 2008-06-23 | 2009-06-22 | 炎症性腸疾患治療剤 |
SI200931585A SI2289518T1 (sl) | 2008-06-23 | 2009-06-22 | Terapevtsko sredstvo za vnetno črevesno bolezen |
LTEP09770108.0T LT2289518T (lt) | 2008-06-23 | 2009-06-22 | Terapinis agentas nuo uždegiminės žarnų ligos |
DK09770108.0T DK2289518T3 (en) | 2008-06-23 | 2009-06-22 | Therapeutic agent for inflammatory bowel diseases |
CA2728161A CA2728161C (en) | 2008-06-23 | 2009-06-22 | Therapeutic agent for inflammatory bowel disease |
ES09770108.0T ES2611483T3 (es) | 2008-06-23 | 2009-06-22 | Agente terapéutico para enfermedad inflamatoria intestinal |
EP09770108.0A EP2289518B1 (en) | 2008-06-23 | 2009-06-22 | Therapeutic agent for inflammatory bowel disease |
US13/000,791 US8394793B2 (en) | 2008-06-23 | 2009-06-22 | Therapeutic agent for inflammatory bowel disease |
CN2009801246843A CN102065864B (zh) | 2008-06-23 | 2009-06-22 | 炎性肠病治疗剂 |
CY20161101341T CY1118390T1 (el) | 2008-06-23 | 2016-12-23 | Θεραπευτικος παραγων για τη φλεγμονωδη νοσο του εντερου |
HRP20170030TT HRP20170030T1 (hr) | 2008-06-23 | 2017-01-10 | Sredstvo za terapiju upalne bolesti crijeva |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008162640 | 2008-06-23 | ||
JP2008-162640 | 2008-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009157398A1 true WO2009157398A1 (ja) | 2009-12-30 |
Family
ID=41444464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/061287 WO2009157398A1 (ja) | 2008-06-23 | 2009-06-22 | 炎症性腸疾患治療剤 |
Country Status (16)
Country | Link |
---|---|
US (1) | US8394793B2 (ja) |
EP (1) | EP2289518B1 (ja) |
JP (1) | JP5527206B2 (ja) |
KR (1) | KR101639821B1 (ja) |
CN (1) | CN102065864B (ja) |
CA (1) | CA2728161C (ja) |
CY (1) | CY1118390T1 (ja) |
DK (1) | DK2289518T3 (ja) |
ES (1) | ES2611483T3 (ja) |
HR (1) | HRP20170030T1 (ja) |
HU (1) | HUE032108T2 (ja) |
LT (1) | LT2289518T (ja) |
PL (1) | PL2289518T3 (ja) |
PT (1) | PT2289518T (ja) |
SI (1) | SI2289518T1 (ja) |
WO (1) | WO2009157398A1 (ja) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010150865A1 (ja) | 2009-06-26 | 2010-12-29 | 日本新薬株式会社 | 結晶 |
WO2011024874A1 (ja) * | 2009-08-26 | 2011-03-03 | 日本新薬株式会社 | 塩基付加塩 |
CN104586853A (zh) * | 2014-12-31 | 2015-05-06 | 武汉联程生物科技有限公司 | 一种用于治疗外伤性颅脑创伤的药物组合物及其制备方法 |
WO2017098998A1 (ja) * | 2015-12-02 | 2017-06-15 | 日本新薬株式会社 | 2-{4-[n-(5,6-ジフェニルピラジン-2-イル)-n-イソプロピルアミノ]ブチルオキシ}-n-(メチルスルホニル)アセトアミドを含有する医薬組成物 |
WO2018162527A1 (en) | 2017-03-08 | 2018-09-13 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition comprising selexipag |
WO2019065792A1 (ja) | 2017-09-28 | 2019-04-04 | 日本新薬株式会社 | 結晶 |
WO2019098300A1 (ja) | 2017-11-16 | 2019-05-23 | 日本新薬株式会社 | 放出制御製剤 |
WO2019154363A1 (zh) | 2018-02-07 | 2019-08-15 | 南京明德新药研发有限公司 | 前列环素受体受体激动剂 |
WO2021078835A1 (en) | 2019-10-23 | 2021-04-29 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition comprising selexipag |
WO2021152060A1 (en) | 2020-01-31 | 2021-08-05 | Actelion Pharmaceuticals Ltd | Controlled release selexipag composition |
WO2022162158A1 (en) | 2021-01-29 | 2022-08-04 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition comprising a diphenylpyrazine derivative |
WO2022162163A1 (en) | 2021-01-29 | 2022-08-04 | Actelion Pharmaceuticals Ltd | Process for manufacturing a diphenylpyrazine derivative |
WO2023131608A1 (en) | 2022-01-04 | 2023-07-13 | Actelion Pharmaceuticals Ltd | Controlled release compositions |
WO2023214059A1 (en) | 2022-05-06 | 2023-11-09 | Actelion Pharmaceuticals Ltd | Diphenylpyrazine compounds as prodrugs |
WO2024017964A1 (en) | 2022-07-20 | 2024-01-25 | Actelion Pharmaceuticals Ltd | Injectable pharmaceutical composition comprising a diphenylpyrazine derivative |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109563055B (zh) * | 2016-07-29 | 2021-12-24 | 成都苑东生物制药股份有限公司 | 氨基吡嗪类化合物或盐、异构体、其制备方法及用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10194992A (ja) * | 1996-12-30 | 1998-07-28 | Fujisawa Pharmaceut Co Ltd | 新規用途 |
WO2002088084A1 (fr) | 2001-04-26 | 2002-11-07 | Nippon Shinyaku Co., Ltd. | Derives de composes heterocycliques et medicaments |
WO2006055481A1 (en) * | 2004-11-16 | 2006-05-26 | Allergan , Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
WO2006058080A1 (en) * | 2004-11-29 | 2006-06-01 | Allergan, Inc. | Treatment of inflammatory bowel disease |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101581059B1 (ko) * | 2008-02-28 | 2015-12-30 | 니뽄 신야쿠 가부시키가이샤 | 섬유화 억제제 |
-
2009
- 2009-06-22 ES ES09770108.0T patent/ES2611483T3/es active Active
- 2009-06-22 JP JP2010517993A patent/JP5527206B2/ja active Active
- 2009-06-22 CA CA2728161A patent/CA2728161C/en active Active
- 2009-06-22 WO PCT/JP2009/061287 patent/WO2009157398A1/ja active Application Filing
- 2009-06-22 HU HUE09770108A patent/HUE032108T2/en unknown
- 2009-06-22 PT PT97701080T patent/PT2289518T/pt unknown
- 2009-06-22 KR KR1020107028238A patent/KR101639821B1/ko active IP Right Grant
- 2009-06-22 EP EP09770108.0A patent/EP2289518B1/en active Active
- 2009-06-22 SI SI200931585A patent/SI2289518T1/sl unknown
- 2009-06-22 LT LTEP09770108.0T patent/LT2289518T/lt unknown
- 2009-06-22 PL PL09770108T patent/PL2289518T3/pl unknown
- 2009-06-22 US US13/000,791 patent/US8394793B2/en active Active
- 2009-06-22 DK DK09770108.0T patent/DK2289518T3/en active
- 2009-06-22 CN CN2009801246843A patent/CN102065864B/zh active Active
-
2016
- 2016-12-23 CY CY20161101341T patent/CY1118390T1/el unknown
-
2017
- 2017-01-10 HR HRP20170030TT patent/HRP20170030T1/hr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10194992A (ja) * | 1996-12-30 | 1998-07-28 | Fujisawa Pharmaceut Co Ltd | 新規用途 |
WO2002088084A1 (fr) | 2001-04-26 | 2002-11-07 | Nippon Shinyaku Co., Ltd. | Derives de composes heterocycliques et medicaments |
WO2006055481A1 (en) * | 2004-11-16 | 2006-05-26 | Allergan , Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
WO2006058080A1 (en) * | 2004-11-29 | 2006-06-01 | Allergan, Inc. | Treatment of inflammatory bowel disease |
Non-Patent Citations (5)
Title |
---|
DIG DIS SCI, vol. 52, 2007, pages 2095 - 2103 |
GASTROENTEROLOGY, vol. 102, 1992, pages 1524 - 1534 |
INT IMMUNOPHARMACOL, vol. 5, 2005, pages 993 - 1006 |
JPN PHARMACOL THER, vol. 36, 2008, pages 293 - 301 |
See also references of EP2289518A4 |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3275871A1 (en) | 2009-06-26 | 2018-01-31 | Nippon Shinyaku Co., Ltd. | Crystals |
EP3689855A1 (en) | 2009-06-26 | 2020-08-05 | Nippon Shinyaku Co., Ltd. | Crystals |
US8791122B2 (en) | 2009-06-26 | 2014-07-29 | Nippon Shinyaku Co., Ltd. | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same |
US9284280B2 (en) | 2009-06-26 | 2016-03-15 | Nippon Shinyaku Co., Ltd. | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
US9340516B2 (en) | 2009-06-26 | 2016-05-17 | Nippon Shinyaku Company, Ltd. | Form-II crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl) acetamide, method for producing the same, and use thereof |
KR20170024165A (ko) | 2009-06-26 | 2017-03-06 | 니뽄 신야쿠 가부시키가이샤 | 결정 |
US9440931B2 (en) | 2009-06-26 | 2016-09-13 | Nippon Shinyaku Co., Ltd. | Form-III crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and use thereof |
WO2010150865A1 (ja) | 2009-06-26 | 2010-12-29 | 日本新薬株式会社 | 結晶 |
WO2011024874A1 (ja) * | 2009-08-26 | 2011-03-03 | 日本新薬株式会社 | 塩基付加塩 |
CN104586853A (zh) * | 2014-12-31 | 2015-05-06 | 武汉联程生物科技有限公司 | 一种用于治疗外伤性颅脑创伤的药物组合物及其制备方法 |
WO2017098998A1 (ja) * | 2015-12-02 | 2017-06-15 | 日本新薬株式会社 | 2-{4-[n-(5,6-ジフェニルピラジン-2-イル)-n-イソプロピルアミノ]ブチルオキシ}-n-(メチルスルホニル)アセトアミドを含有する医薬組成物 |
JPWO2017098998A1 (ja) * | 2015-12-02 | 2018-09-20 | 日本新薬株式会社 | 2−{4−[n−(5,6−ジフェニルピラジン−2−イル)−n−イソプロピルアミノ]ブチルオキシ}−n−(メチルスルホニル)アセトアミドを含有する医薬組成物 |
US10821108B2 (en) | 2015-12-02 | 2020-11-03 | Nippon Shinyaku Co., Ltd. | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
RU2735547C2 (ru) * | 2015-12-02 | 2020-11-03 | Ниппон Синяку Ко., Лтд. | Фармацевтическая композиция, содержащая 2-{ 4-[n-(5,6-дифенилпиразин-2-ил)-n-изопропиламино]бутилокси} -n-(метилсульфонил)ацетамид |
US10828298B2 (en) | 2015-12-02 | 2020-11-10 | Nippon Shinyaku Co., Ltd. | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide |
WO2018162527A1 (en) | 2017-03-08 | 2018-09-13 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition comprising selexipag |
KR20200060393A (ko) | 2017-09-28 | 2020-05-29 | 니뽄 신야쿠 가부시키가이샤 | 결정 |
US11655218B2 (en) | 2017-09-28 | 2023-05-23 | Nippon Shinyaku Co., Ltd. | Crystalline substituted pyrazines as PGI2 receptor agonists |
KR20240042215A (ko) | 2017-09-28 | 2024-04-01 | 니뽄 신야쿠 가부시키가이샤 | 결정 |
WO2019065792A1 (ja) | 2017-09-28 | 2019-04-04 | 日本新薬株式会社 | 結晶 |
US10906879B2 (en) | 2017-09-28 | 2021-02-02 | Nippon Shinyaku Co., Ltd. | Crystalline substituted pyrazines as PGI2 receptor agonists |
KR20200088382A (ko) | 2017-11-16 | 2020-07-22 | 니뽄 신야쿠 가부시키가이샤 | 방출 제어 제제 |
JPWO2019098300A1 (ja) * | 2017-11-16 | 2020-11-19 | 日本新薬株式会社 | 放出制御製剤 |
US11382912B2 (en) | 2017-11-16 | 2022-07-12 | Nippon Shinyaku Co., Ltd. | Controlled-release preparation |
WO2019098300A1 (ja) | 2017-11-16 | 2019-05-23 | 日本新薬株式会社 | 放出制御製剤 |
US11299475B2 (en) | 2018-02-07 | 2022-04-12 | Medshine Discovery Inc. | Prostacyclin receptor agonist |
WO2019154363A1 (zh) | 2018-02-07 | 2019-08-15 | 南京明德新药研发有限公司 | 前列环素受体受体激动剂 |
WO2021078835A1 (en) | 2019-10-23 | 2021-04-29 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition comprising selexipag |
WO2021152060A1 (en) | 2020-01-31 | 2021-08-05 | Actelion Pharmaceuticals Ltd | Controlled release selexipag composition |
WO2022162158A1 (en) | 2021-01-29 | 2022-08-04 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition comprising a diphenylpyrazine derivative |
WO2022162163A1 (en) | 2021-01-29 | 2022-08-04 | Actelion Pharmaceuticals Ltd | Process for manufacturing a diphenylpyrazine derivative |
WO2023131608A1 (en) | 2022-01-04 | 2023-07-13 | Actelion Pharmaceuticals Ltd | Controlled release compositions |
WO2023214059A1 (en) | 2022-05-06 | 2023-11-09 | Actelion Pharmaceuticals Ltd | Diphenylpyrazine compounds as prodrugs |
WO2024017964A1 (en) | 2022-07-20 | 2024-01-25 | Actelion Pharmaceuticals Ltd | Injectable pharmaceutical composition comprising a diphenylpyrazine derivative |
Also Published As
Publication number | Publication date |
---|---|
KR101639821B1 (ko) | 2016-07-14 |
PL2289518T3 (pl) | 2017-03-31 |
CN102065864A (zh) | 2011-05-18 |
CA2728161A1 (en) | 2009-12-30 |
EP2289518A1 (en) | 2011-03-02 |
HRP20170030T1 (hr) | 2017-03-24 |
CY1118390T1 (el) | 2017-06-28 |
CN102065864B (zh) | 2012-11-21 |
JPWO2009157398A1 (ja) | 2011-12-15 |
US20110118254A1 (en) | 2011-05-19 |
US8394793B2 (en) | 2013-03-12 |
DK2289518T3 (en) | 2017-01-16 |
KR20110036537A (ko) | 2011-04-07 |
EP2289518A4 (en) | 2012-04-11 |
HUE032108T2 (en) | 2017-08-28 |
CA2728161C (en) | 2017-06-06 |
SI2289518T1 (sl) | 2017-02-28 |
LT2289518T (lt) | 2017-01-10 |
EP2289518B1 (en) | 2016-11-02 |
ES2611483T3 (es) | 2017-05-09 |
PT2289518T (pt) | 2016-11-18 |
JP5527206B2 (ja) | 2014-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5527206B2 (ja) | 炎症性腸疾患治療剤 | |
WO2009157397A1 (ja) | 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤 | |
JP5527205B2 (ja) | 脊柱管狭窄症治療剤 | |
WO2009154246A1 (ja) | 勃起不全治療剤 | |
JP5522030B2 (ja) | 線維化抑制剤 | |
EP1949902B1 (en) | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | |
US6967211B2 (en) | Remedial agent for chronic articular rheumatism | |
BR112017019805B1 (pt) | Composto, composição farmacêutica, e uso para fabricar uma composição farmacêutica para melhorar, prevenir ou tratar dor, ansiedade ou depressão, mal de parkinson, polaquiúria ou incontinência urinária e glaucoma | |
US20140163013A1 (en) | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome | |
CN103102348B (zh) | 噁二唑类化合物及其制备方法、药物组合物及其用途 | |
TW406083B (en) | Novel piperazine derivatives | |
KR100911069B1 (ko) | 치환된 알킬아미노피리다지논 유도체, 이의 제조 방법 및이를 함유하는 약제학적 조성물 | |
JP2016516714A (ja) | 呼吸制御調節化合物およびそれを使用する方法 | |
ZA200107244B (en) | Benzamide derivatives and drugs containing the same | |
JP2012092079A (ja) | 育毛剤 | |
KR20120037035A (ko) | 위 음식물 수용능 장해 치료약 | |
WO2022211052A1 (ja) | 歩行障害治療剤 | |
JP7010404B1 (ja) | 歩行障害治療剤 | |
WO2024012572A1 (zh) | 一种杂芳基衍生物的药物组合物及其在医药上的应用 | |
WO2009128479A1 (ja) | イミダゾリン誘導体 | |
WO2021203779A1 (zh) | 治疗肺动脉高压的化合物及其应用 | |
JPH083045A (ja) | 排尿障害改善薬 | |
JP2001354656A (ja) | ヒドロキシホルムアミジン化合物及びその塩並びにそれらを含む医薬 | |
JP2007512267A (ja) | 高尿酸血症の治療のためのペンタジエン酸誘導体の使用 | |
JPH0543466A (ja) | 悪液質改善治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980124684.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09770108 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010517993 Country of ref document: JP |
|
REEP | Request for entry into the european phase |
Ref document number: 2009770108 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009770108 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107028238 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2728161 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13000791 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |